"The lead protection we wear is causing a lot of damage," SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, explained in an interview.

The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.

Citing evidence from documents and interviews, the Guardian released an exposé accusing UnitedHealth of directly influencing the day-to-day operations of some 2,000 nursing homes, resulting in patients not receiving necessary emergency care.

COVID-19 vaccines are associated with a very low risk of myocarditis and/or pericarditis, primarily in young adults. The long-term impact of this risk has been the subject of many studies and debates over the years. One side says that the benefits of vaccination far outweigh the risks, and the other side says that even the smallest risk of heart damage is too high.

Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.

ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.

The FDA is revising its approach to COVID-19 vaccine approvals, moving away from the previous trend of treating boosters like annual flu shots. Health researcher Vinay Prasad and Commissioner Martin Makary argue in the New England Journal of Medicine for more rigorous data requirements and additional clinical studies to justify future inoculations for those under 65. 

One of the world's largest medtech companies could make a major move within the next 18 months. Que Dallara, the current president of Medtronic’s diabetes business, would be the new company's CEO.